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Background  and  aims:  Injecting  drug  use  is  a  chronic  condition,  with  people  who  inject  drugs  (PWID)
typically  experiencing  repeated  cessations  and  relapses  during  their injection  careers.  We  characterize
patterns  of  ceasing  and  relapsing  and  the  impact  of  opiate  substitution  treatment  (OST)  during  the entire
injecting  careers  of PWID  in  the  Edinburgh  Addiction  Cohort  (EAC).
Methods:  During  2005–2007,  432  surviving  participants  of  the  EAC  were  interviewed  about  their injecting
histories.  Adjusted  associations  between  covariates  and  hazards  of  cessation  and  relapse  were  estimated
using  random-effects  models.
Results:  OST  was  strongly  associated  with  a higher  hazard  of  cessation  (HR  =  1.71,  P < 0.001),  but there
was  no  signiﬁcant  evidence  of  association  with  hazard  of  relapse  (HR  = 0.81,  P = 0.14).  Women  and  older
PWID were  less  likely  to relapse  (HR  =  0.73,  P = 0.02  and  HR  =  0.55, P  <  0.001,  respectively).  Hazards  of both
cessation  and relapse  decreased  monotonically  with  time  since  last  relapse/cessation  (both  P < 0.001).  An
individual’s  hazard  of  cessation  increased  with  his/her  number  of  previous  cessations  (HR  = 3.58  for  10+
previous  cessations,  P <  0.001),  but there  was  no  evidence  that  an  individual’s  hazard  of relapse  changed
with  number  of  previous  relapses  (P  = 0.37).  There  was  heterogeneity  in  the  individual  hazards  of  both
cessation  and  relapse.
Conclusions:  OST  was  associated  with  reduced  time  to cessation,  and  there  was  some  suggestion  of
increased  time  to  relapse  too.  The  likelihood  of prolonged  cessation  is  greater  for women,  increases
with  age,  and  decreases  with  time  since  last  relapse.
Crown  Copyright  © 2015  Published  by  Elsevier  Ireland  Ltd.  This  is  an  open  access  article  under  the  CC. Introduction
Injecting drug use is an important public health problem in
any countries (Mathers et al., 2008, 2010). People who inject
rugs (PWID) have over 10 times greater risk of premature mor-
ality than the general population and may  contribute over 10% of
eaths among young people (Bargagli et al., 2006; Degenhardt et al.,
010a). PWID are at increased risk of HIV and Hepatitis C virus
∗ Corresponding author at: School of Social and Community Medicine, University
f  Bristol, Canynge Hall, 39 Whatley Road, Bristol BS8 2PS,
K. Tel.: +44 (0)117 928 7252.
ttp://dx.doi.org/10.1016/j.drugalcdep.2015.03.005
376-8716/Crown Copyright © 2015 Published by Elsevier Ireland Ltd. This is an open acBY  license  (http://creativecommons.org/licenses/by/4.0/).
infection in many countries (Alter and Moyer, 1998; De Angelis
et al., 2009; Degenhardt et al., 2010b), and contribute substan-
tially to the costs of crime and imprisonment (Godfrey and Eaton,
2002; Godfrey et al., 2004). Opiate substitution treatment is criti-
cal to reduction of drug related harm (Amato et al., 2005; van den
Berg et al., 2007; Cornish et al., 2010; Degenhardt et al., 2010a;
Gossop et al., 2005; Gowing et al., 2011; Turner et al., 2011) but its
long-term effect on injecting cessation is uncertain.
PWID typically experience repeated periods of injecting and
cessation, and have been characterized as a chronic health prob-
lem (McLellan et al., 2000; O’Brien, 2011; O’Brien and McLellan,
1996). An alternative perspective on the natural history of drug
addiction has emphasized it as a problem starting in adolescence
cess article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Fig. 1. The assignment of non-injection periods for the 405 PWID in the EAC, United
Kingdom, 1980–2006. (a) A single period of non-injection preceded by a period ofY. Xia et al. / Drug and Alcoh
hat people can ‘mature out of’ in adulthood Harding et al., 1980;
addux and Desmond, 1980, 1986; Winick, 1962, 1964, highlight-
ng that some individuals will cease before becoming dependent
r only after a short period of injecting (Biernacki, 1986; Robbins
t al., 1975; Sweeting et al., 2009; Zinberg and Jacobson, 1976).
The duration of injecting, likelihood of long-term cessation and
he factors that promote cessation and recovery are important both
o policy on drug treatment and assessments of disease burden,
ut these quantities remain uncertain. In part this is because long-
erm follow-up and natural history studies of opiate and injecting
rug use are rare. In this study we examine patterns of ceasing and
elapsing during the entire injecting career, and explore associa-
ions between opiate substitution treatment and other covariates
nd risks of recovery and relapse.
. Material and methods
.1. Data source
The Edinburgh Addiction Cohort (EAC) is a prospective open
ohort study of 794 opiate injectors recruited by Muirhouse Med-
cal Group from 1980 to 2006 (Kimber et al., 2010; Macleod et al.,
010; Robertson et al., 1994; Skidmore et al., 1990). Information
n opiate substitution treatment (OST) use (methadone, buprenor-
hine or dihyrocodeine) and age at onset was extracted from
rimary care case notes (Cornish et al., 2010; Robertson et al., 2006).
n 2005–2007, the surviving participants were interviewed about
heir past patterns of injecting. A full account of this cohort is given
lsewhere (Copeland et al., 2004; Macleod et al., 2010; Robertson
t al., 1986; Robertson and Richardson, 2007). Case notes were
vailable for 655 (83%) individuals (22 had no contact details, 30
ot traced, 38 no response, 40 declined, 9 too ill). Of these, 223
ad died before interview and 27 others had missing year of onset
f injection. Here we focus on the 405 remaining individuals. For
hese 405 individuals, the mean (standard deviation, SD) number
f years from recruitment to interview was 10.8 (7.2) and that from
ear of ﬁrst injection to interview was 17.6 (9.0).
During the interviews, individuals ﬁlled out retrospective life
rids indicating, for each calendar year since beginning to inject,
hether they had injected in that year. For each year that an indi-
idual reported injecting, the individual was asked whether there
as a period lasting at least 3 months in that year during which
e/she did not inject (a ‘non-injection period’). If there was such
 period, the individual was asked to estimate the number of dis-
inct such non-injection periods and the total number of days spent
njecting in that year (Macleod et al., 2010). Periods of abstinence
hat lasted less than 3 months were not elicited. Interviews were
nchored around memorable events (e.g. death of father, divorce)
o aid recall (Macleod et al., 2010).
.2. Cessation and relapse times
An injection career can be thought of as a sequence of recurrent
vents in which the injector switches repeatedly between injection
nd non-injection. We  deﬁne a ‘cessation’ as the beginning of a
on-injection period, and deﬁne a ‘relapse’ as the end of such a
eriod. The data available from the interview questionnaires did
ot determine precisely when cessations and relapses occurred. So
nstead we used the following algorithm to impute these times. This
lgorithm aims to minimize the number of cessations and relapses,
y assuming, whenever possible, that two periods of non-injecting
eported in consecutive calendar years corresponded to a single
ontinuous period of non-injecting spanning the new year. Fig. 1
llustrates the algorithm.injecting. (b) A single period of non-injection preceded by a period of non-injection.
(c)  Two non-injection periods within 1 year. (d) Three non-injection periods within
1  year.
For each individual, the algorithm begins by taking each calen-
dar year in turn, in chronological order, and assigning non-injection
periods in that year to the beginning, middle or end of the year.
When there is only one non-injection period in the year, it is placed
at the end of that year if the preceding year ended with an inject-
ing period (Fig. 1a), and at the beginning of the year otherwise (Fig.
1b). When there are two non-injection periods, one is put at the
beginning of the year and one at the end (Fig. 1c). When there are
three non-injection periods, they are put at the beginning, mid-
dle, and end (Fig. 1d). The exact beginning and end times of these
non-injecting periods (i.e. times of cessation and relapse) are then
imputed by partitioning the total number of days that the individ-
ual reported not injecting in that calendar year equally between
the 1–3 non-injecting periods.
2.3. Statistical analysis
The Kaplan–Meier estimator was  used to estimate the distri-
bution of time from injection onset to ﬁrst cessation and of the
subsequent time to the next relapse.
Random-effects proportional-hazards models were used to
investigate the dependence of the hazards of cessation and relapse
on covariates, accounting for correlation between repeated times
to event (cessation or relapse) within the same individual (Aalen
et al., 2008). The time-constant covariates were sex, age at injec-
tion onset, and year of injection onset (before or after 1986); the
time-varying covariates were current OST use, number of previous
cessations/relapses, and current age. OST was  a time-varying three-
level categorical variable taking values ‘currently prescribed OST’,
‘not currently prescribed OST’ or ‘unknown whether currently pre-
scribed OST’ (or ‘on OST’, ‘off OST’ and ‘unknown OST’ for short).
Year of injection onset was  dichotomized at 1986 because this is
when HIV test became widely available, which may have altered
injecting behavior. Data on all these covariates except OST use were
obtained during the interview.
The model for relapse is as follows (that for cessation is analo-
gous). Let hij(t) denote the hazard of relapse for individual i at time
t during his/her jth non-injection period (where time zero means
7 ol Dependence 151 (2015) 76–83
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eginning of that period). Let OSTon,ij(t) equal 1 if individual i is on
ST at that time, and 0 otherwise. Similarly, let OSTna,ij(t) equal 1
f the individual has unknown OST status at that time, and 0 oth-
rwise, and let Z ij(t) denote the values of the remaining covariates
sex, current age, etc.) at that time. Then a basic random-effects
roportional hazards model is given by
ij(t) = h0(t) exp[ˇonOSTon,ij(t) + ˇnaOSTna,ij(t) + ˇZZ ij(t) + ui]
here h0(t) is the baseline hazard, and ui is a random-effect spe-
iﬁc to individual i. The random effects are assumed to be normally
istributed with mean zero. A positive random effect ui implies
hat individual i has a greater baseline hazard of relapse than the
verage individual; negative ui implies a lower than average haz-
rd of relapse. Parameters ˇon and ˇna are the log hazard ratios
f relapse when on OST and unknown OST, respectively, com-
ared to when off OST; and ˇZ are the log hazard ratios of the
emaining covariates. Log hazard ratios greater than zero (or, equiv-
lently, hazard ratios greater than one) imply a shorter expected
ime to relapse, and so shorter non-injection period; log hazard
atios less than zero (equivalently, hazard ratios less than one)
mply a longer expected time to relapse, and so longer non-injection
eriod.
The baseline hazard h0(t) for relapse was assumed to be
iecewise-constant over four intervals: ≤2 months, (2, 12] months,
1, 2] years, and more than 2 years. For cessation, ﬁve intervals
ere used: ≤3 days, (3, 7] days, (1, 12] weeks, (3, 12] months, and
ore than 1 year. These change points were chosen by examining
lots of the cumulative hazards. This procedure was further aided
y comparing nested models with increasing number of change
oints using likelihood ratio tests so that non-signiﬁcant change
oints could be dropped.
A potential problem with this basic model is ‘confounding by
luster’ (Seaman et al., 2014). The basic model above assumes
hat the probability that individual i is on OST at any given time
 (OSTon,ij(t) = 1) is uncorrelated with his/her random effect ui. In
ractice, however, it is possible that an individual with a high ran-
om effect for relapse (and so who tends to relapse quickly after
essation) may  be more likely to be prescribed OST than another
ndividual who has a lower random effect (and so who  tends to
elapse slower). This can cause difﬁculties with both interpretation
nd estimation of the OST effect parameters ˇon and ˇna (Seaman
t al., 2014). To deal with this potential problem of confounding by
luster, we used the Poor Man’s method of Neuhaus and Kalbﬂeisch
1998). This involves separating each of the OST effects ˇon and ˇna
nto a between-individual and a within-individual effect, which is
chieved by replacing the basic model above with
hij(t) = h0(t) exp[ˇBon ¯OSTon,i + ˇWon{OSTon,ij(t) − ¯OSTon,i}
+ˇBna ¯OSTna,i + ˇWna{OSTna,ij(t) − ¯OSTna,i} + ˇZZ ij(t) + ui]
here ¯OSTon,i and ¯OSTna,i denote the fractions of individual i’s total
ollow-up spent on OST and with unknown OST, respectively. The
arameter ˇBon describes the between-individual effect of being on
ST, i.e. the log hazard ratio comparing two different individuals:
he average individual who spends all his/her time on OST and the
verage individual who spends no time on OST. The parameter ˇWon
escribes the within-individual effect of being on OST, i.e. the log
azard ratio of the same individual at two different times: when
n OST and when off OST. The between- and within-individual
ffects of having unknown OST, ˇBna and ˇ
W
na, are analogous. Within-ndividual effects are of more interest than between-individual
ffects, because individuals who spend a lot of time on OST may
iffer in many unmeasured ways from individuals who spend little
ime on OST.Fig. 2. Histograms of the total number and rate of transitions for the 405 PWID in
the  EAC, United Kingdom, 1980–2006.
Finally, we carried out two sensitivity analyses. First, we ﬁtted
a Cox model with random effects, in order to avoid assuming a
piecewise-constant form for h0(t). Second, we ﬁtted a joint model
for cessation and relapse, allowing the random effects for cessa-
tion and relapse to be correlated. This enabled us to check that
such a correlation was not causing bias due to violation of our
model’s independent censoring assumption (Xia, 2013). The hazard
ratio estimates and P values for OST and other covariates obtained
from both these models were similar to those from the model
described above, and so we do not report them here. The models
with piecewise-constant hazard were ﬁtted by maximum likeli-
hood in STATA (StataCorp, 2009) and, for the joint model, in R
using bespoke code (Core Team, 2014); the Cox model with ran-
dom effects was  ﬁtted using the coxme package in R (Therneau,
2012).
3. Results
Fig. 2 (top) shows the distribution of the total number of
transitions (either cessation or relapse) per individual during the
follow-up period. The median (interquartile range, IQR) of the total
number of transitions (either cessation or relapse) per individual
during the follow-up period was 3 (1–4); the mean (SD) was  5 (9)
and the maximum was  81. Eighteen (4%) individuals made no tran-
sitions, i.e. they injected throughout follow-up; 65 (16%) injected
for less than 1 year with no further relapse; and 252 (65%) expe-
rienced at least one relapse. Fig. 2 (bottom) shows the distribution
of the total number of transitions per individual divided by his/her
years of follow-up.
3.1. Kaplan–Meier curves
The Kaplan–Meier estimated probability that a ﬁrst-time injec-
tor ceased within 12 months was  0.46 (95% CI: 0.41, 0.50) (Fig. 3),
and within 5 years was 0.72 (95% CI: 0.67, 0.76). The estimated
median (IQR) time to ﬁrst cessation was  1.5 (0.0–5.6) years. The
estimated probability of subsequent relapse was  0.37 (95% CI: 0.32,
0.42) at 12 months and 0.59 (95% CI: 0.53, 0.63) at 5 years (Fig. 4).
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Table  1
Estimated associations between covariates and hazards of cessation and relapse among the EAC, United Kingdom, 1980–2006.
Cessation Relapse
HRa 95% CIa P-value HR 95% CI P-value
Sex
Male (Ref) 1.00 1.00
Female 1.05 0.81, 1.36 0.71 0.73 0.56, 0.94 0.02
Age  at injection onset
12–19 (Ref) 1.00 1.00
20+ 1.32 0.99, 1.76 0.06 1.40 1.08, 1.83 0.01
Year  of injection onset
<1986 (Ref) 1.00 1.00
≥1986 1.37 1.05, 1.80 0.02 1.21 0.94, 1.58 0.14
Current age 0.62 0.001
<20  0.94 0.74, 1.18 0.59 1.06 0.78, 1.44 0.73
20–25  (Ref) 1.00 1.00
26–30  0.96 0.79, 1.16 0.66 0.70 0.57, 0.87 0.001
31–35  1.10 0.87, 1.39 0.41 0.77 0.61, 0.98 0.04
35+  1.15 0.85, 1.56 0.37 0.55 0.41, 0.75 <0.001
OST  exposure
Between-individual <0.001 0.007
Not  on OST (Ref) 1.00 1.00
On  OST 0.73 0.53, 1.02 0.07 1.67 1.16, 2.40 0.006
Unknown 0.35 0.21, 0.57 <0.001 1.95 1.18, 3.23 0.01
Within-individual <0.001 0.14
Not  on OST (Ref) 1.00 1.00
On  OST 1.71 1.40, 2.09 <0.001 0.81 0.65, 1.00 0.05
Unknown 1.11 0.81, 1.54 0.52 0.83 0.59, 1.18 0.30
No.  of previous cessations/relapses <0.001 0.37
0  (Ref) 1.00 1.00
1–2  1.19 0.97, 1.47 0.09 1.27 1.00, 1.62 0.05
3–4  1.52 1.14, 2.03 0.005 1.36 0.96, 1.92 0.09
5–9 2.67 1.94, 3.69 <0.001 1.44 0.97, 2.14 0.07
≥10  3.58 2.42, 5.29 <0.001 1.54 0.96, 2.48 0.08
Baseline hazard for cessation <0.001
≤3 days (Ref) 1.00
(3, 7] days 0.51 0.40, 0.64 <0.001
(1,  12] weeks 0.09 0.08, 0.11 <0.001
(3,  12] months 0.04 0.03, 0.05 <0.001
>1  year 0.03 0.03, 0.04 <0.001
Baseline hazard for relapse <0.001
≤2  months (Ref) 1.00
(2,  12] months 0.87 0.74, 1.03 0.11
(1,  2] years 0.38 0.30, 0.50 <0.001
>2  years 0.10 0.08, 0.13 <0.001
Variance of log-normal random effects 0.90 0.65, 1.24 <0.001 0.57 0.33, 0.98 <0.001
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ia CI, conﬁdence interval; HR, hazard ratio.
he estimated median (IQR) time to subsequent relapse was 2.4
0.5–23.8) years.
.2. Regression models
Table 1 shows the estimated hazard ratios from the proportional
azards models with piecewise-constant baseline hazards. Opiate
ubstitution treatment (OST) use was associated with higher hazard
f cessation within an individual (HR = 1.71 for on OST, 95% CI: 1.40,
.09, overall P < 0.001 from likelihood-ratio test on 2 degrees of free-
om). The between-individual effect of OST provides evidence of
onfounding (with hazard ratios in the opposite direction to within-
ndividual effects), suggesting that those people who  cease slower
ay  also be those more likely to be prescribed OST. An individual’s
azard of cessation increased with his/her number of previous ces-
ations (overall P < 0.001): compared to the ﬁrst injection period,
he hazard was 1.19 times as large (95% CI: 0.97, 1.47) during the
econd and third periods, and was 3.58 times as large (95% CI: 2.42,
.29) after the 10th period. People who inject drugs (PWID) who
egan injecting after 1986 had a higher hazard (HR = 1.37, 95% CI:
.05, 1.80, P = 0.02). There was weak evidence that PWID who began
njecting at an older age (≥20) had a higher hazard of cessation(HR = 1.32, 95%CI: 0.99, 1.76, P = 0.06). No evidence of the hazard
differing by gender or current age has been found.
For hazard of relapse, there was some suggestion of a within-
individual effect of OST (HR = 0.81 for on OST), but this was
non-signiﬁcant (overall P = 0.14). The between-individual effect of
OST (HR = 1.67 for on OST, overall P = 0.007) was  signiﬁcant, which
is probably again due to confounding: those PWID who  relapse
faster are also those who are more likely to be prescribed OST.
Women  had a lower hazard of relapse (HR = 0.73, 95% CI: 0.56,
0.94, P = 0.02). Current age was  also signiﬁcantly associated with
hazard (overall P = 0.001), with the hazard after age 35 years drop-
ping to 55% of that at age <20 years (HR = 0.55, 95% CI: 0.41, 0.75).
PWID who began injecting at an older age (≥20) had a higher haz-
ard of relapse (HR = 1.40, 95% CI: 1.08, 1.83, P = 0.01). There was  no
evidence that an individual’s hazard differed by calendar period
of onset or changed as the number of his/her previous relapses
increased.
The hazards of both cessation and relapse were monotonically
decreasing with time since last relapse/cessation (overall P < 0.001
for both). The hazard of cessation during (3, 7] days since last
relapse was only 0.51 (95% CI: 0.40, 0.64) times the hazard dur-
ing [1, 3] days. Thereafter the hazard continued to decline, with the
hazard ratio reaching 0.03 after 1 year (95% CI: 0.03, 0.04) compared
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Fig. 3. Kaplan–Meier estimate of time to ﬁrst cessation for the 405 PWID in the EAC,
United Kingdom, 1980–2006.
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interview data using the algorithm described in Section 2, becauseig. 4. Kaplan–Meier estimate of time to ﬁrst relapse for the 405 PWID in the EAC,
nited Kingdom, 1980–2006.
o that during [1, 3] days. The hazard of relapse (1, 2] years after
ost recent cessation was only 0.38 (95% CI: 0.30 and 0.50) times
he hazard after ≤2 months; after 2 years this hazard ratio had
ecreased to 0.10 (95% CI: 0.08, 0.13).
We found evidence for signiﬁcant heterogeneities in the hazards
f cessation and relapse between individuals: variances of random
ffects were 0.90 (95% CI: 0.65, 1.24, P < 0.001) and 0.57 (95% CI:
.33, 0.97, P < 0.001), respectively.endence 151 (2015) 76–83
4. Discussion
We  found evidence of a strong inverse association between
being on opiate substitution treatment (OST) and the average
duration of injection episodes. There was  insufﬁcient evidence,
however, that OST exposure reduced the risk of relapse. Women
had lower rates of relapse than men. Age was positively associated
with lower rates of relapse but not with time to cessation. An indi-
vidual’s rate of cessation increased as he/she accumulated more
previous cessations, but there was little evidence that his/her rate
of relapse changed as he/she accumulated more previous relapses.
The risk of cessation or relapse is not constant but decreases with
time elapsed since the previous relapse or cessation, respectively.
For example, the risk of relapse after more than 2 years of non-
injecting was  10% of the risk at the start of a period of non-injecting.
Thus, the likelihood that an individual experiences long-term ces-
sation, though not explicitly modeled, increases with age, number
of previous cessation events, and the duration of non-injecting.
There was  evidence of heterogeneity in the individual risks of both
cessation and relapse.
4.1. Strengths and limitations
The Edinburgh Addiction Cohort (EAC) features a long period
of follow-up (median 18.5 years). This has enabled us to examine
long-term injecting patterns and to extend the analysis of patterns
of injecting beyond ﬁrst cessation and relapse.
However, our ﬁndings are subject to several limitations and
potential biases. First, the cohort may  under-represent people who
inject drugs (PWID) for very short periods, because they may  be
less likely to experience health or other problems and therefore
less likely to come to the attention of primary care. EAC partici-
pants were enrolled on the basis that they report injecting drug
use or present with drug related problems in primary care; and
though time from onset to recruitment was shorter for EAC than
for many other cohorts (Macleod et al., 2010) there is likely to be
some selection bias. For instance, approximately 16% of EAC report
injecting periods of less than 1 year, which is slightly lower than
the proportion estimated from other studies of between 20% and
50% (Sweeting et al., 2009), suggesting the potential for under-
ascertainment.
Second, there is likely to be survivor bias, as information on tran-
sitions between injection and non-injection is available only for
those who survived long enough to attend the interview. Unfortu-
nately, the information from clinical notes on injecting patterns
is not sufﬁciently complete to allow periods of injecting/non-
injecting to be identiﬁed for the deceased cases (Macleod et al.,
2012). The times to cessation and relapse and the impact of the
covariates on these times, therefore, may  differ for people who
have not survived. Although the model presented in this paper
does not include a long-term cessation state, we showed earlier
that the effect of covariates on time to long-term cessation was
not biased by excluding deceased cohort participants (Kimber et al.,
2010).
Third, there also may  be recall bias, since the data on these
transitions were collected retrospectively through a single ques-
tionnaire. We  tried addressing the recall bias by including a
categorical variable for decades (e.g. 1960s, 70s, 80s, etc.) in the
regression model; the regression results were little affected and
hence this variable for decades was  excluded in the model pre-
sented.
Fourth, cessation and relapse times were imputed from thedata on injecting periods were limited to the number of non-
injecting periods in each calendar year. The algorithm minimizes
the number of transitions, which may  have caused the hazards of
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essation and relapse to be underestimated. In addition, some of
he cessations and relapses that we imputed as occurring when
WID were on OST may  actually have occurred when they were off
ST, and vice versa. This misclassiﬁcation could cause bias in the
stimated hazard ratios of OST. However, there are two reasons to
elieve that this will have little impact on our conclusions. Firstly,
he data on OST use came from the case notes, rather than from
nterviews, and the method of imputing cessation/relapse times
ade no use of these OST data. Thus, any misclassiﬁcation would
e expected to dilute any true association between OST use and
azard of cessation or relapse, rather than to create an apparent
ssociation where none exists. Secondly, the main factor deter-
ining the estimated hazard ratios of OST is the total numbers of
essations/relapses occurring while on OST, off OST and unknown
ST. 94% of both the imputed cessations and the imputed relapses
ook place in calendar years during which PWID were entirely on
ST, entirely off OST or had entirely unknown OST status. For these
essations and relapses, moving the imputed time to earlier or later
n the year would not change whether they occurred when on, off
r unknown OST, and so would not change the total numbers of
essations/relapses occurring while on OST, off OST and unknown
ST.
Fifth, biases could have been introduced to the associations pre-
ented in Table 1 due to confounding by omitted time-dependent
ehavioral covariates, such as incarceration history. These data
ere poorly recorded in primary care notes and also unavailable
hrough record linkage (Macleod et al., 2012).
.2. Implications and other evidence
Out of the few longitudinal studies of injecting heroin use, most
ave tended to emphasize the persistence and high rates of relapse
nd high mortality rates associated with injecting heroin use (Galai
t al., 2003; Goldstein and Herrera, 1995; Hser et al., 2001; Kimber
t al., 2010; Rathod et al., 2005; Stimson and Oppenheimer, 1982;
ermorshuizen et al., 2005a; Vaillant, 1973). Only a few stud-
es have tried to characterize the injection career and explored
actors that may  inﬂuence injecting duration, notably the Amster-
am Cohort Study (ACS), the AIDS Link to Intravenous Experience
ALIVE) cohort in Baltimore and California Civil Addict Program
CAP) (Galai et al., 2003; Hser et al., 2007; Nosyk et al., 2013; Shah
t al., 2006; Termorshuizen et al., 2005b; Vlahov et al., 1991). The
LIVE and ACS cohorts both have reported high rates of cessation
nd relapse during follow-up and that OST was associated with
 faster time to cessation. For example, Shah et al. (2006) found
hat 86% of the non-injection/occasional use periods were followed
y relapse within 5 years and estimated median time to cessa-
ion and relapse was 4 and 1 year respectively. Termorshuizen
t al. (2005b) in an analysis of the ACS also found that OST was
ssociated with longer injecting careers and did not appear to
romote ‘long-term cessation’. In addition, Nosyk et al. (2013)
ssessing the CAP showed that long-term cessation or sustained
bstinence often occurs after multiple periods of recovery and
elapse, and that previous number of abstinent events and age are
ssociated with duration of abstinence and time to next recovery
vent.
Galai et al. (2003) described several classes of injector based on
ersistence and number of relapses and found that group mem-
ership was associated with history of incarceration, age, and OST
xposure. However, their classiﬁcation of injecting patterns could
otentially bias the inferences, as length of follow-up may  be a con-
ounder for the relationship between the risk factors and injecting
roup membership. In addition, these previous analyses examine
ime to cessation after recruitment rather than from injecting onset
hich our analyses suggest may  introduce bias since number of
revious cessations and age are associated with time to cessationendence 151 (2015) 76–83 81
and hazard of relapse respectively. It has been argued that a
lack of association between injecting patterns and age or episode
number is consistent with the thesis that addiction is a ‘chronic
relapsing problem’ rather than a problem ‘that people mature out
of’ (Langendam et al., 2000; McLellan et al., 2000; Termorshuizen
et al., 2005b; van den Berg et al., 2007; Winick, 1962). We  do
ﬁnd evidence of an association between cessation and relapse
with age and episode number. However, very few of our cohort
members remain ‘untreated’ and therefore can be considered
as ceasing ‘naturally’ (if this is construed as without treatment)
and so our ﬁndings also are consistent with a chronic relapsing
disease.
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